programme
view preliminary programme
Friday, 27th June 2025
14:00 - 18:00
Registration
OPENING LECTURE: Chair: Karam Kostner and Martin Clodi
18:00-18:30
Time is of the essence: never mind future drugs, use what you have available to fullest extent and lower cardiovascular risk aggressively. - Peter Toth
18:30-19:00
What will change the LL landscape in the next 5 years – Maciej Banach
19:00
Welcome Reception
Saturday, 28th June 2025
08:00
Registration
08:30 - 10:00
PLENARY SESSION 1: LDL - Chair: Steve Nicholls and Derek Connolly
08:30 - 09:00
LDL lowering in 2025: Optimal approach – Dereck Connolly
09:00 - 09:30
Novel LDL therapies: What is on the horizon? TBC
09:30 - 10:00
Gene Therapies: Lifetime cure for CVD – Christof Fellmann
10:00 - 10:30
Sponsored Symposium: ARROWHEAD Triglycerides
10:30 - 11:00
Coffee Break, Exhibition and E-poster Viewing
11:00 - 12:30
Parallel Sessions:
Workshop 1
Familial Hypercholesterolemia: joint session with the Austrian Atherosclerosis Society
Chairs: Gerald Watts and Hans Dieplinger
Workshop 2
Imaging Atherosclerosis and risk prediction
Chairs: Warrick Bishop and Walter Speidl
11:00 - 11:30
FH: Genetics, Epidemiology: Steve Humphries
Can Cardiac CT guide lipid management? Warrick Bishop
11:30 - 12:00
Lessons from the Norwegian FH registry: Martin Borgsrud
Risk Scores and CV risk prediction algorithms: Walter Speidl
12:00 - 12:20
Newborn Screening: Caroline Bachmaier
Polygenic Risk Scores: Florian Kroenenberg
12:20 - 12:30
„Austrian FH registry - update“
Azin Kheirkhah
12:30 - 13:30
PLENARY SESSION 2: Lp(a) – Chair: Florian Kroneneberg and Gert Kostner
12:30 – 12:40
Introductory remarks: Gert Kostner
12:40-13:10
Epidemiology, Genetics, Measurement: Florian Kronenberg
13:10 – 13:30
How to treat elevated Lp(a): Karam Kostner
13:30 - 14:30
Lunch Break / Exhibition and E-Poster Viewing
14:30 - 15:00
Sponsored Symposium: Lp(a) in daily clinical practice
Florian Kronenberg and Yvonne Winhofer
15:00 – 16:30
Parallel Sessions
Workshop 3
Diets and Nutraceuticals
Chairs: David Colquhoun and Maciej Banach
Workshop 4
Proteomic markers, remnants and HDL:
Chairs: Caroline Bachmaier and Florian Kronenberg
15:00 – 15:30
What is the best diet for elevated LDL and TG? - TBC
The role of proteomic Markers in cardiovascular Risk Assessment – Winfried Maerz
15:30 – 16:00
Nutraceuticals to lower LDL and TG – Maciej Banach
Comprehensive update on remnant lipoproteins and HDL: Peter Toth
16:00 – 16:30
Role of Omega 3 FA: EPA, DHA or both? – David Colquhoun
Novel biomarkers: TBC
16:30 - 17:00
Coffee Break, Exhibition and E-poster Viewing
17:00 – 18:30
PLENARY SESSION 3: TG, parallel session for chylomicronemia syndromes,
Chairs: Gerald Watts and Peter Toth
17:00 – 17:30
Defining features and pathophysiology of Chylomicronemia syndromes: Gerald Watts
17:30 – 18:00
State of the art management of chylomicronemia syndromes – Peter Toth
20:00
Gala Dinner
Sunday, 29th June 2025
08:00 - 17:00
Registration
08:30 – 10:00
PLENARY SESSION 4: What Clinicians must know about lipids in 2025
08:30 – 08:45
Genetic Dyslipidemias: Steve Humphries
08:45 – 09:00
LDL: Karam Kostner
09:00 – 09:15
Lp(a): Florian Kronenberg
09:15 – 09:30
Risk Assessment: Warrick Bishop
09:30 – 09:45
TG: Peter Toth
09:45 – 10:00
Panel Discussion
10:00 - 10:30
Coffee Break, Exhibition and E-poster Viewing
10:30 – 12:30
Sponsored Symposium: Amarin
"Mechanistic insights into cardio protection with EPA"
Chair: Univ. Prof. Dr. Georg Speidl
10:30 - 12:30
Parallel Sessions:
Workshop 5
Diabetic Dyslipidemia; Joint Session with Austrian Diabetes Society
Chairs: Natalie Koh and Peter Fasching
Workshop 6
Inflammation
Chairs: Winfried Maerz and Christopher Binder
10:30 – 11:00
Diabetic Dyslipidemia: Beyond LDL – Atherogenic Lipoproteins in Focus: Gersina Rega Kaun
Role of Inflammation in Atherosclerosis: Christoph BiInder
11:00 – 11:30
Effects of GLP-1 Receptor Agonists and SGL T2 Inhibitors on Lipid Metabolism: Bernhard Ludvik
Inflammatory Biomarkers: lessons from Luric: Winfried Maerz
11:30 – 12:00
Lipoprotein(a) in Diabetes: A Neglected Cardiovascular Risk Factor? : Natalie Koh
Focus on residual risk by targeting inflammation – who should we treat?
12:00 – 12:30
Targeting Triglycerides in Diabetes: Do We Need a Paradigm Shift? Thomas Stulnig
12:30 - 13:30
Lunch Break / Exhibition and E-Poster Viewing
13:30 - 15:00
PLENARY SESSION 5: Various
Chairs: Peter Toth and Kurt Derfler
13:30 – 13:50
SiRNA therapies: Challenges and opportunities: Derek Connolly
13:50 – 14:10
CV risk in Women: Elena Osto
14:10 – 14:30
Apheresis: For which patients in 2025: TBC
14:30-14:45
Management od dyslipidemia in Pregnancy: Maciej Banach
14:45-15:00
Management of dyslipidemia in children: TBC
15:00 - 15:30
Lunch Break / Exhibition and E-Poster Viewing
15:30 – 17:00
PLENARY SESSION 6: Case based discussions
Chairs: Maciej Banach and David Colquhoun
15:30 – 17:00
Rare cases submitted by participants and ad board
16:00 - 16:30
Closing remarks
key topics
Classification and Detection of Dyslipidemias
Lipid Guidelines
Atherosclerosis Imaging
Familial Dyslipidemias
Difficult to treat Hyperlipidemia
Statin Resistance/Intolerance
Lipid Control in Diabetes and Metabolic Syndrome
Diet and Neutraceuticals
Novel Drugs
HDL, TG, Lp(a)
Apheresis
scientific committee
NATIONAL (AUSTRIA)
Martin Clodi
University Professor
Specialist in Internal Medicine
Head of the Internal Medicine Department, BHB Linz
Florian Kronenberg
Head of Institute of Genetic Epidemiology
Florian Kronenberg
Florian Kronenberg received his MD from the University of Innsbruck, Austria. After his training in Medical Genetics in Gerd Utermann's lab, he worked with Roger R. Williams and Steve Hunt at the University of Utah, USA. Later, he headed the Research Unit "Genetic Epidemiology" at the Helmholtz-Center Munich. In 2004, he became full professor and head of the Institute of Genetic Epidemiology at the Medical University of Innsbruck. He is a Member of the Academia Europaea.
His main research interests are genetic and clinical epidemiological studies on lipoprotein(a) as one of the most important genetic risk factors for cardiovascular disease. His team has probably the largest collection of samples with more than 40.000 individuals with in depth characterization of the LPA gene including data from Western blot analyses.
He is Co-Editor of "Atherosclerosis" and served as workgroup member on several guideline and consensus initiatives (K/DOQI, KDIGO and EAS). He chaired the most recent EAS Consensus Statement on Lp(a) (together with Samia Mora and Erik Stroes).
Florian Kronenberg has published roughly 500 papers including 400 original papers and about 90 review articles, editorials and book chapters. He has an H-index of 96 (Scopus) and 112 (Google Scholars) with roughly 51,000 citations.
Walter Speidl
Clinical cardiologist and intensivist at the Medical University of Vienna in Austria
Walter Spedil
Associate Professor Dr. Walter Speidl is clinical cardiologist and intensivist at the Medical University of Vienna in Austria. He started his residency at the Medical University of Vienna in 2003 and was research fellow at the Mount Sinai School of Medicine, New York from 2006 to 2008. In 2014 he finished his clinical fellowships for cardiology and for intensive care medicine. He is working as deputy chair of the medical intensive care unit and as interventionist. In 2018 he founded a dedicated cardiac lipid clinic to improve secondary prevention of high-risk patients and is its head since then. His clinical research focuses on lipids and biomarkers of inflammation and thrombosis in stable coronary artery disease and acute coronary syndromes. In addition, he devotes his time on basic research regarding the interplay of innate immunity and thrombosis in critical ill patients and in the pathogenesis of atherosclerosis and acute coronary events.
Christoph Binder
Professor at Medical University of Vienna
Prof. Christoph Binder
Professor of Atherosclerosis Research
Department of Laboratory Medicine
Medical University of Vienna, Austria
Christoph J. Binder (born 1973) received his MD degree from the University of Vienna, Austria, in 1997 and his PhD degree in Molecular Pathology from the University of California San Diego (UCSD), USA, in 2002. Following postdoctoral training at the Department of Medicine of UCSD, he established his own research group at the Department of Laboratory Medicine of the Medical University of Vienna in 2005. In 2009, he was appointed Full Professor of Atherosclerosis Research at the Medical University of Vienna. He is a specialist in Laboratory Medicine and currently Deputy Head of the Department of Laboratory Medicine at the Medical University of Vienna. Between 2006 until 2021 he was Principal Investigator at the Center for Molecular Medicine of the Austrian Academy of Sciences. Christoph Binder’s research interests span the interface of vascular biology, lipid oxidation, and immunity. His group is investigating immune mechanisms of atherosclerosis with a special focus on the role of innate and humoral immunity and how this can be exploited for the treatment of cardiovascular disease. Christoph Binder has won numerous prestigious fellowships and awards and has authored >200 original and review papers in important international journals, including Nature and Nature Medicine. He is Co-Editor of Atherosclerosis and Section Editor of Thrombosis & Haemostasis, and since 2017 PI of the Austrian Familial Hypercholesterolemia Registry. Since 2024 he acts as Vice President for Biology and Medicine of the Austrian Science Fund.
Gert Kostner
University Professor at Medical University of Graz
Kurt Derfler
thomas stuling
Dr. Thomas Stulnig
University Professor
Specialist in Internal Medicine, Endocrinology & Diabetology
Head Department of Medicine III, Clinic Hietzing, Vienna
International
Maciej Banach
Head of Cardiovascular Research Centre at University of Zielona Gora. Cardiologist, Prorector for Collegium Medicum, the John Paul II, Catholic University of Lublin, Lublin, Poland
Maciej Banach
Prof. Maciej Banach is a Vice-Rector for Collegium Medicum in the John Paul II Catholic University of Lublin (KUL) and Head of Department of Preventive Cardiology and Lipidology at the Medical University of Lodz (MUL). He is also an Adjunct Professor at the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, and Senior Research Fellow at the Liverpool Centre for Cardiovascular Sciences (LCCS). He is a Founder and Head of the Polish Lipid Association (PoLA), Founder of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, and President of the International Lipid Expert Panel (ILEP). Prof. Banach is within 1% the highest cited scientists in the world according to Essential Science Indicators by Clarivate (with 76 TOP Papers) and one of the most cited scientist in Poland with 97,354, IH=109 acc. Web of Science Core Collection, and 175,577 citations, IH=146 acc. Google Scholar. He is a laureate of several prizes and award, including: the Most Influential Person in Medicine in Poland for year 2023 on the Top 100 list by Puls Medycyny journal (2024), and 5 recognitions of Doctor Honoris Causa (at the Universities in Zagreb, Kosice, Bucharest, Kiev, and Timisoara).
Stephen Nicholls
Cardiologist and Researcher focused on developing new strategies to reduce the burden of cardiovascular disease
Stephen Nicholls
Professor Stephen (Steve) Nicholls is a cardiologist and researcher focused on developing new strategies to reduce the burden of cardiovascular disease. His major research interests include studying the impact of metabolic factors influencing heart disease, development of novel plaque imaging modalities in clinical practice and performing large scale clinical trials of novel cardioprotective therapies.
Currently based in Melbourne, Steve is leading the Victorian Heart Hospital project, an Australian first state-of-the-art specialist cardiac hospital. Located on the Monash University Clayton campus, the hospital will integrate clinical cardiology services, research (housing the Victorian Heart Institute) and education to create a centre of excellence, raising the profile of cardiovascular research, treatment and training.
Warrick Bishop
Practicing cardiologist, best selling author, and keynote speaker and who has a passion to help prevent heart disease on a global scale.
Warrick Bishop
Doctor Warrick Bishop is a practicing cardiologist, best selling author, and keynote speaker and who has a passion to help prevent heart disease on a global scale.
What if you could plan NOT to have a heart attack?
Dr Warrick Bishop, a widely renowned practicing cardiologist, is on a mission to help patients do just that. He’s spoken on TEDx stages and sat on countless interviews, including 60 Minutes and ABC Radio, delivering eye-opening insights that have enabled patients to have meaningful conversations about their heart health with their doctors and valuable information on life-changing technological advancements that could impact patients’ health.
By using both advocacy and the latest in emerging technologies for earlier detection and assessment of those at risk for heart attack. If you or someone you know is near the age of 40, have a family history of heart attacks, or are worried about a heart attack then you should read this book... It just may save your life or the life of somebody you love.
Author Doctor Warrick Bishop is a 3-Time #1 International Best Selling Author and Cardiologist with a special interest in cardiovascular disease prevention incorporating imaging, lipids, and lifestyle.
Graduating from the University of Tasmania, School of Medicine, in 1988. He worked in the Northern Territory and South Australia before completing his advanced training in cardiology in Hobart, Tasmania, becoming a Fellow of the Royal Australian College of Physicians and Member of the Cardiac Society of Australia and New Zealand in 1997. Working predominately in private practice. In 2009 Warrick undertook training in CT Cardiac Coronary Angiography, being the first cardiologist in Tasmania with this specialist recognition.
Doctor Warrick Bishop shares his unique perspective on using non-invasive imaging technology and provides a concise plan in preventing a heart attack.
Natalie Koh
Consultant Cardiologist (NHCS) | Medical Advisor (WhiteCoat Global)
Derek Connolly
Prof BSc [1st Cl. Hons] MB ChB [Edin] PhD [Cantab] DSc[Hon] FRCP FESC is a Consultant Cardiologist at Birmingham City Hospital
Derek Connolly
Prof Derek Connolly BSc [1st Cl. Hons] MB ChB [Edin] PhD [Cantab] DSc[Hon] FRCP FESC is a Consultant Cardiologist at Birmingham City Hospital, Birmingham UK. He trained in Cambridge, London, Edinburgh and San Diego where he was a Carnegie Scholar. He has a first class degree in Pharmacology from the University of Edinburgh where he was the Brunton medallist and Keasbey Bursary holder. His PhD in molecular cardiology is from the University of Cambridge. He is the Chief or Primary Investigator of multiple large trials in Cardiovascular medicine. He developed one of the UKs first primary angioplasty programmes, and one of the UKs largest cardiac CT programmes. He is a Fellow of the European Society of Cardiology.
Prof Connolly's private practice is based at the Priory Hospital, Edgbaston, Birmingham
Caroline Bachmeier
CAROLINE BACHMEIER
Caroline is a Chemical Pathologist and Endocrinologist based in Brisbane. She completed her medical training in Germany, Spain and the UK prior to emigrating to Australia. She enjoys all aspects of clinical endocrinology and laboratory medicine and has developed an interest in lipid diagnostics and management. She is currently undertaking research in the field of newborn screening for FH.
Affiliations:
University of Queensland, Brisbane, Australia
Sullivan Nicolaides Pathology, Brisbane, Australia
Royal Brisbane and Women's Hospital, Brisbane, Australia
Gerald Watts
Peter Toth
